Chinese Journal of Dermatology ›› 2022, e20220172.doi: 10.35541/cjd.20220172

• Reviews • Previous Articles     Next Articles

Biotherapy for cutaneous squamous cell carcinoma

Ji Xiang, Wang Daguang   

  1. Department of Dermatology and Venereology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China
  • Received:2022-03-15 Revised:2022-08-26 Online:2022-01-01 Published:2022-11-11
  • Contact: Wang Daguang
  • Supported by:
    National Natural Science Foundation of China (81000703, 81472896); Natural Science Foundation of Jiangsu Province (BK2009437); Six Talent Peaks of Jiangsu Province (2015-WSW-026)

Abstract: 【Abstract】 Since cemiplimab was approved by United States Food and Drug Administration in 2018, anti-programmed cell death receptor-1 antibodies have been considered as the first-line systemic therapy for advanced cutaneous squamous cell carcinoma. This review focuses on current clinical application of targeted therapy, immunotherapy, targeted immunotherapy and gene therapy in cutaneous squamous cell carcinoma.

Key words: Carcinoma, squamous cell, Skin, Molecular targeted therapy, Immunotherapy, Biotherapy